Unused PhilHealth Funds – Legal, Ethical, and Historical Considerations in Secretary Herbosa’s Controversial Move

By Louis ‘Barok‘ C Biraogo — August 26, 2024

SHOULD billions of pesos intended for healthcare be returned to the national government? That’s the question at the heart of a heated controversy surrounding Health Secretary Teodoro Herbosa’s decision to reclaim P89.9 billion in unused funds from PhilHealth. Herbosa, a respected public health professional, argues that the funds should revert to the national government, but his decision has sparked intense debate, raising legal, ethical, and financial concerns.

The Man and the Crisis: Secretary Herbosa and the PhilHealth Fund Controversy

Secretary Herbosa’s career is marked by dedication to public health and significant achievements, particularly in strengthening the healthcare system during the COVID-19 pandemic. However, his recent decision regarding the transfer of unused PhilHealth funds to the national government has embroiled him in a significant controversy. As the chairperson of the PhilHealth board, Herbosa’s stance that these funds are not savings or member contributions but government subsidies that PhilHealth failed to utilize, has drawn scrutiny from various quarters.

The Rules of the Game: Legal Precedents and Regulatory Framework

The legal argument for reclaiming unused PhilHealth funds hinges on the interpretation of multiple legal frameworks, including the General Appropriations Act (GAA) and the Universal Health Care Act (RA 11223). Herbosa and the Department of Health (DOH) argue that under the GAA, excess funds from government-owned and controlled corporations (GOCCs) like PhilHealth must be returned to the national coffers. This view is reinforced by previous rulings of the Commission on Audit (COA), which has disallowed the retention of funds by GOCCs when they are not utilized as intended. For instance, in the COA’s decision in Philippine National Oil Company vs. COA, the court upheld the disallowance of retained earnings that were not used for their specified purpose, setting a precedent for the return of unused subsidies.

Conversely, critics of this move might invoke the Universal Health Care Act, particularly Section 11, which mandates that excess reserves of PhilHealth should be directed towards increasing benefits or reducing member contributions. The legal challenge here lies in the DOH’s interpretation that the unspent subsidies do not constitute reserves. This interpretation could be contested, as was the case in Philippine Health Insurance Corporation vs. DOH, where the court underscored the agency’s autonomy in managing its funds, provided they serve the public interest.

Data and Evidence: Financial Autonomy vs. Public Interest

The debate over financial autonomy versus public interest is at the heart of this controversy. Over the past three years, PhilHealth has reportedly accumulated P89.9 billion in unused subsidies. These funds, according to Herbosa, are in excess of the agency’s actual requirements, raising questions about the efficiency of fund utilization within PhilHealth. However, reallocating these funds to other public services must be weighed against the potential impact on PhilHealth’s financial stability and its ability to expand healthcare benefits.

Data from PhilHealth’s financial reports suggest that while the agency’s reserves remain robust, the unused funds could have been critical in expanding services, particularly in a healthcare system still reeling from the pandemic. For instance, the expansion of benefits for cancer treatment, which includes a nearly 1,000% increase in coverage limits, could potentially be constrained if PhilHealth’s financial autonomy is compromised.

Alternative Perspectives: Voices from the Healthcare Sector

The controversy also warrants attention to the perspectives of healthcare professionals, patient advocacy groups, and independent experts. Many in the healthcare sector express concern that the transfer of unused funds could set a dangerous precedent, undermining PhilHealth’s ability to operate independently and effectively. Healthcare professionals argue that the national government’s reallocation of these funds might lead to a shortfall in future healthcare financing, particularly as the country continues to grapple with long-term health challenges exacerbated by the pandemic.

Patient advocacy groups, on the other hand, emphasize the importance of ensuring that every peso allocated to healthcare is used efficiently and transparently. They argue that if PhilHealth cannot utilize these funds effectively, then reallocating them to other critical public services is justifiable, provided that it does not compromise the quality and accessibility of healthcare.

Historical Context: A Troubled History of PhilHealth Fund Management

This is not the first time PhilHealth has been embroiled in controversy over fund management. In 2020, PhilHealth was accused of mismanagement and corruption, leading to a Senate investigation and the resignation of key officials. These historical challenges in fund management lend weight to the argument for greater oversight and stricter regulation of PhilHealth’s financial operations.

The current debate, therefore, must be viewed in light of this history. While PhilHealth’s autonomy is crucial for the effective delivery of healthcare services, the government’s role in ensuring accountability and the efficient use of public funds cannot be overlooked.

Conclusion: Balancing Legal, Ethical, and Financial Considerations

In evaluating the arguments, it is clear that both sides present compelling points. Herbosa’s assertion that the unused funds belong to the national government is legally sound, particularly when viewed through the lens of the General Appropriations Act and previous COA rulings. However, the potential risks to PhilHealth’s financial autonomy and the broader implications for healthcare services cannot be dismissed.

To strike a balance, the government could consider a more nuanced approach, such as earmarking a portion of the returned funds for specific health-related programs while ensuring that PhilHealth retains sufficient resources to fulfill its mandate. Additionally, greater transparency and accountability in PhilHealth’s financial management could help restore public trust and prevent future controversies.

For Secretary Herbosa, navigating this controversy will require a careful balancing of legal obligations, ethical considerations, and the long-term needs of the Philippine healthcare system. The recommendations for all concerned include reinforcing PhilHealth’s financial oversight mechanisms, ensuring transparent fund allocation, and fostering a collaborative approach between the DOH and PhilHealth to optimize healthcare delivery for all Filipinos.